2/6/2006

Australian investment professionals believe the country's biotech industry may be turning the corner from one plagued with false starts and disappointments to one producing milestones with more products entering late-stage trials. But the sector remains a risky one with a long wait for a payback and still requires careful research on the part of the investor.

Related Summaries